Table 3.
ExeOW Study | LS mean body weight decrease (kg) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
ExeOW | ExeBID | SITA | PIO | GLAR | MET | PIO | SITA | LIRA | DET | |
DURATION-1 [8] | −3.7 | −3.6 | ||||||||
DURATION-2 [12] | −2.3 | −0.3 § | 2.8 ¶ | |||||||
DURATION-3 [13] | −2.6 | 1.4* | ||||||||
DURATION-4 [11] | −2 | −2 | 1.5* | 0.3* | ||||||
DURATION-5 [14] | −2.3 | −1.4 | ||||||||
DURATION-6 [15] | −2.7 | −3.6 |
EXEOW exenatide once weekly, EXEBID exenatide twice a day, SITA sitagliptin, PIO pioglitazone, GLAR insulin glargine, MET metformin, LIRA liraglutide, DET insulin detemir
* p < 0.001, § p = 0.0002, ¶ p < 0.0001